A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
← catalyst calendarNCT07023302 · readout ≤ 924 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
125actual
Sites
15
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-19 | actual | When the study began enrolling |
| Primary completion | Feb 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: Upadacitinib
- Drug: Upadacitinib Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 10
measured Week 24
Number of Participants with Adverse Events (AEs)
measured Up to approximately 108 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed